Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing.
Authors
Ljungman, PDe Witte, T
Verdonck, L
Gahrton, G
Freycon, F
Gravett, P
McCann, S
Morgenstern, Godfrey R
Nikoskelainen, J
Powles, R
Affiliation
Department of Medicine, Huddinge University Hospital, Sweden.Issue Date
1993-05
Metadata
Show full item recordAbstract
The optimal post-remission therapy for patients with acute myeloblastic leukaemia remains controversial. Allogeneic bone marrow transplantation, autologous bone marrow transplantation, and consolidation chemotherapy are the major options. In order to evaluate their respective value the European Group for Bone Marrow Transplantation conducted a prospective registration study. Patients with newly diagnosed acute myeloblastic leukaemia were registered at the time of HLA-typing and intention to treat in case of presence or absence of an HLA-identical donor was recorded. 27/79 (34%) patients HLA-typed at diagnosis had an identical donor identified. The estimated survivals at 3 years from HLA-typing were 44% and 21% among patients with or without HLA-identical donor, respectively (P = 0.02). 22/26 (85%) patients for whom allogeneic bone marrow transplantation was intended were transplanted but only 15/47 (32%) patients for whom autologous bone marrow transplantation was intended were indeed transplanted (P < 0.001). The survival was 50%, 29% and 17% (P = 0.004) for patients treated with allogeneic bone marrow transplantation, autologous bone marrow transplantation, or chemotherapy, respectively. 40/68 patients HLA-typed in first complete remission had an HLA-identical donor. The estimated 3-year survival among patients typed in first remission with and without HLA-identical donors was 42% and 35% (n.s.), respectively. This technique of early patient registration illustrates the problems of patient selection during the course of the disease and might be used as a complement to randomized trials when comparing bone marrow transplantation and other treatment options.Citation
Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing. 1993, 84 (1):61-6 Br. J. Haematol.Journal
British Journal of HaematologyDOI
10.1111/j.1365-2141.1993.tb03025.xPubMed ID
8338779Type
ArticleLanguage
enISSN
0007-1048ae974a485f413a2113503eed53cd6c53
10.1111/j.1365-2141.1993.tb03025.x
Scopus Count
Collections
Related articles
- Bone marrow transplantation for acute myeloid leukemia: the EBMT experience. A prospective analysis from HLA-typing. The EMBT Leukemia Working Party.
- Authors: Gratwohl A, Ljungman P, de Witte T, Verdonck L, Freyçon F, Gravett P, McCann S, Morgenstern HG, Nikoskelainen J, Powles R
- Issue date: 1992
- Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) Study.
- Authors: Ringdén O, Labopin M, Gluckman E, Hows JM, Bradley BA, Kolb HJ, Fouillard L, Jacobsen N, Vernant JP, Witz F, Harousseau JL, Gorin NC
- Issue date: 1997 May
- No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
- Authors: Cahn JY, Labopin M, Sierra J, Blaise D, Reiffers J, Ferrant A, Bergmann L, Visani G, Cornelissen J, De Witte T, Bosi A, Frassoni F, Gorin NC
- Issue date: 2000 Aug
- Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial.
- Authors: Reiffers J, Gaspard MH, Maraninchi D, Michallet M, Marit G, Stoppa AM, Corront B, David B, Gastaut JA, Scotto JJ
- Issue date: 1989 May
- Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
- Authors: Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G
- Issue date: 1995 Jan 26